Follow
Stefania Sartini
Stefania Sartini
Verified email at unipi.it
Title
Cited by
Cited by
Year
Pyrido[1,2-a]pyrimidin-4-one Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors Exhibiting Antioxidant Activity
C La Motta, S Sartini, L Mugnaini, F Simorini, S Taliani, S Salerno, ...
Journal of Medicinal Chemistry 50 (20), 4917-4927, 2007
1542007
FOXD1–ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells
P Cheng, J Wang, I Waghmare, S Sartini, V Coviello, Z Zhang, SH Kim, ...
Cancer research 76 (24), 7219-7230, 2016
1422016
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic …
R Ottaną, R Maccari, M Giglio, A Del Corso, M Cappiello, U Mura, ...
European journal of medicinal chemistry 46 (7), 2797-2806, 2011
1322011
Sampling protein motion and solvent effect during ligand binding
V Limongelli, L Marinelli, S Cosconati, C La Motta, S Sartini, L Mugnaini, ...
Proceedings of the National Academy of Sciences 109 (5), 1467-1472, 2012
1172012
Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer
A Antonelli, G Bocci, C La Motta, SM Ferrari, P Fallahi, A Fioravanti, ...
The Journal of Clinical Endocrinology & Metabolism 96 (2), E288-E296, 2011
1002011
Design, synthesis and biological evaluation of new classes of thieno [3, 2-d] pyrimidinone and thieno [1, 2, 3] triazine as inhibitor of vascular endothelial growth factor …
E Perspicace, V Jouan-Hureaux, R Ragno, F Ballante, S Sartini, ...
European journal of medicinal chemistry 63, 765-781, 2013
712013
Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states
G Perugi, C Toni, G Ruffolo, S Sartini, E Simonini, H Akiskal
Pharmacopsychiatry 32 (04), 136-141, 1999
641999
How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase
M Zentgraf, H Steuber, C Koch, C La Motta, S Stefania, C Sotriffer, ...
ANGEWANDTE CHEMIE. INTERNATIONAL EDITION 46 (19), 3575-3578, 2007
622007
Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors
F Da Settimo, G Primofiore, C La Motta, S Sartini, S Taliani, F Simorini, ...
Journal of medicinal chemistry 48 (22), 6897-6907, 2005
622005
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model
C La Motta, S Sartini, S Salerno, F Simorini, S Taliani, AM Marini, ...
Journal of medicinal chemistry 51 (11), 3182-3193, 2008
582008
CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo
A Antonelli, G Bocci, C La Motta, SM Ferrari, P Fallahi, I Ruffilli, ...
The Journal of Clinical Endocrinology & Metabolism 97 (4), E528-E536, 2012
542012
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
A Antonelli, G Bocci, P Fallahi, C La Motta, SM Ferrari, C Mancusi, ...
The Journal of Clinical Endocrinology & Metabolism 99 (4), E572-E581, 2014
532014
Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors
C La Motta, S Sartini, L Mugnaini, S Salerno, F Simorini, S Taliani, ...
Journal of medicinal chemistry 52 (6), 1681-1692, 2009
532009
Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure− activity relationship analysis, and virtual screening …
C La Motta, S Sartini, T Tuccinardi, E Nerini, F Da Settimo, A Martinelli
Journal of medicinal chemistry 52 (4), 964-975, 2009
502009
Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step
A Ramunno, S Cosconati, S Sartini, V Maglio, S Angiuoli, V La Pietra, ...
European journal of medicinal chemistry 51, 216-226, 2012
482012
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening
S Cosconati, L Marinelli, C La Motta, S Sartini, F Da Settimo, AJ Olson, ...
Journal of Medicinal Chemistry 52 (18), 5578-5581, 2009
442009
A new approach to control the enigmatic activity of aldose reductase
A Del-Corso, F Balestri, E Di Bugno, R Moschini, M Cappiello, S Sartini, ...
PLoS One 8 (9), e74076, 2013
432013
Evidence for a novel binding site conformer of aldose reductase in ligand-bound state
H Steuber, M Zentgraf, C La Motta, S Sartini, A Heine, G Klebe
Journal of molecular biology 369 (1), 186-197, 2007
412007
Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells
L Quattrini, ELM Gelardi, V Coviello, S Sartini, DM Ferraris, M Mori, ...
Journal of Medicinal Chemistry 63 (9), 4603-4616, 2020
402020
From pollen grains to functionalized microcapsules: a facile chemical route using ionic liquids
C Chiappe, GC Demontis, V Di Bussolo, MJR Douton, F Rossella, ...
Green chemistry 19 (4), 1028-1033, 2017
362017
The system can't perform the operation now. Try again later.
Articles 1–20